{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:46:56Z","timestamp":1790293616149,"version":"4.1.0"},"reference-count":49,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merz Therapeutics GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>This analysis pooled pain severity data from four phase 3 and 4 studies of incobotulinumtoxinA (incoBoNT-A) for the treatment of cervical dystonia (CD) in adults. CD-related pain severity was assessed at baseline, each injection visit, and 4 weeks after each injection of incoBoNT-A using the Toronto Western Spasmodic Torticollis Rating Scale pain severity subscale or a pain visual analog scale. Both were analyzed using a score range of 0\u201310 and pain was categorized as mild, moderate, or severe. Data for 678 patients with pain at baseline were assessed and sensitivity analyses evaluated pain responses in the subgroup not taking concomitant pain medication (n = 384 at baseline). At Week 4 after the first injection, there was a mean change of \u22121.25 (standard deviation 2.04) points from baseline pain severity (p &lt; 0.0001), with 48.1% showing \u2265 30% pain reduction from baseline, 34.4% showing \u226550% pain reduction from baseline, and 10.3% becoming pain free. Pain responses were sustained over five injection cycles with a trend to incremental improvements with each successive cycle. Pain responses in the subgroup not taking concomitant pain medication demonstrated the lack of confounding effects of pain medications. These results confirmed the pain relief benefits of long-term treatment with incoBoNT-A.<\/jats:p>","DOI":"10.3390\/toxins15050333","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T09:26:13Z","timestamp":1683883573000},"page":"333","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pain Reduction in Cervical Dystonia Following Treatment with IncobotulinumtoxinA: A Pooled Analysis"],"prefix":"10.3390","volume":"15","author":[{"given":"Alberto","family":"Albanese","sequence":"first","affiliation":[{"name":"Department of Neurology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6238-3578","authenticated-orcid":false,"given":"J\u00f6rg","family":"Wissel","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation and Physical Therapy, Vivantes Hospital Spandau, 13585 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-3297","authenticated-orcid":false,"given":"Wolfgang H.","family":"Jost","sequence":"additional","affiliation":[{"name":"Parkinson-Klinik Ortenau, 77709 Wolfach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Castagna","sequence":"additional","affiliation":[{"name":"IRCCS Fondazione Don Carlo Gnocchi, 20148 Milano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Althaus","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, 60318 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Comes","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, 60318 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4745-0853","authenticated-orcid":false,"given":"Astrid","family":"Scheschonka","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, 60318 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Vacchelli","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, 60318 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyder A.","family":"Jinnah","sequence":"additional","affiliation":[{"name":"Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Albanese, A., Kailash, K.P., Cardoso, F., Comella, C., Defazio, G., Fung, V.S.C., Hallett, M., Jankovic, J., Jinnah, H.A., and Kaji, R. (2023). Isolated cervical dystonia: Diagnosis and classification. Mov. Disord., in press.","DOI":"10.1002\/mds.29387"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/mdc3.13524","article-title":"The prevalence of idiopathic or inherited isolated dystonia: A systematic review and meta-analysis","volume":"9","author":"Medina","year":"2022","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00415-014-7586-2","article-title":"An international survey of patients with cervical dystonia","volume":"262","author":"Comella","year":"2015","journal-title":"J. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1007\/s00415-018-9119-x","article-title":"Quality of life in idiopathic dystonia: A systematic review","volume":"266","author":"Girach","year":"2019","journal-title":"J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00415-014-7343-6","article-title":"Cervical dystonia and pain: Characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy)","volume":"261","author":"Charles","year":"2014","journal-title":"J. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.3390\/toxins7062321","article-title":"Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment","volume":"7","author":"Camargo","year":"2015","journal-title":"Toxins"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1515\/revneuro-2018-0119","article-title":"Pain in cervical dystonia and the antinociceptive effects of botulinum toxin: What is currently known?","volume":"30","author":"Marciniec","year":"2019","journal-title":"Rev. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1080\/00207454.2020.1860039","article-title":"Targeting pain in the long-term treatment of cervical dystonia with botulinum toxin A","volume":"132","author":"Marciniec","year":"2022","journal-title":"Int. J. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14737175.2021.1984230","article-title":"Pain in cervical dystonia: Mechanisms, assessment and treatment","volume":"21","author":"Rosales","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000069635","article-title":"Pain in cervical dystonia","volume":"Volume 14","author":"Jost","year":"2003","journal-title":"Botulinum Toxin in Painful Diseases. Pain Headache"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.parkreldis.2016.08.014","article-title":"Determinants of disability in cervical dystonia","volume":"32","author":"Tijssen","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2018.04.030","article-title":"Pain in focal dystonias\u2014A focused review to address an important component of the disease","volume":"54","author":"Avenali","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","article-title":"EFNS guidelines on diagnosis and treatment of primary dystonias","volume":"18","author":"Albanese","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00415-015-7703-x","article-title":"Practical guidance for CD management involving treatment of botulinum toxin: A consensus statement","volume":"262","author":"Albanese","year":"2015","journal-title":"J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fneur.2017.00035","article-title":"Clinical practice: Evidence-based recommendations for the treatment of cervical dystonia with botulinum toxin","volume":"8","author":"Contarino","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Spiegel, L.L., Ostrem, J.L., and Bledsoe, I.O. (2020). FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. Toxins, 12.","DOI":"10.3390\/toxins12050332"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00702-020-02266-z","article-title":"Botulinum toxin therapy of dystonia","volume":"128","author":"Dressler","year":"2021","journal-title":"J. Neural. Transm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","article-title":"A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(\u00ae)) in cervical dystonia","volume":"120","author":"Evidente","year":"2013","journal-title":"J. Neural. Transm."},{"key":"ref_22","first-page":"tre-03-140-2921-1","article-title":"Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-na\u00efve subjects with cervical dystonia","volume":"3","author":"Fernandez","year":"2013","journal-title":"Tremor. Other Hyperkinet. Mov."},{"key":"ref_23","first-page":"CD003633","article-title":"Botulinum toxin type A therapy for cervical dystonia","volume":"11","author":"Rodrigues","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/papr.12408","article-title":"Neck pain and cervical dystonia: Treatment outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy)","volume":"16","author":"Charles","year":"2016","journal-title":"Pain Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2017.02.042","article-title":"Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry","volume":"376","author":"Trosch","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_26","first-page":"100063","article-title":"Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice","volume":"3","author":"Trosch","year":"2020","journal-title":"Clin. Park Relat. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/jnnp-2012-303608","article-title":"Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia","volume":"84","author":"Dressler","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_28","first-page":"100142","article-title":"Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study","volume":"6","author":"Comella","year":"2022","journal-title":"Clin. Park Relat. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/pm\/pnz017","article-title":"Pain pathways and nervous system plasticity: Learning and memory in pain","volume":"20","author":"McCarberg","year":"2019","journal-title":"Pain Med."},{"key":"ref_30","first-page":"tre-03-193-4374-2","article-title":"Descriptive epidemiology of cervical dystonia","volume":"3","author":"Defazio","year":"2013","journal-title":"Tremor. Other Hyperkinet. Mov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"116413","DOI":"10.1016\/j.jns.2019.07.031","article-title":"Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study","volume":"405","author":"Dashtipour","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J. Pain"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia","volume":"16","author":"Truong","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"117015","DOI":"10.1016\/j.jns.2020.117015","article-title":"Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study","volume":"416","author":"Colosimo","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/WNF.0b013e31826538c7","article-title":"Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia","volume":"35","author":"Charles","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00702-012-0887-7","article-title":"Rating scales for cervical dystonia: A critical evaluation of tools for outcome assessment of botulinum toxin therapy","volume":"120","author":"Jost","year":"2013","journal-title":"J. Neural. Transm."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Costanzo, M., Belvisi, D., Berardelli, I., Maraone, A., Baione, V., Ferrazzano, G., Cutrona, C., Leodori, G., Pasquini, M., and Conte, A. (2021). Effect of botulinum toxin on non-motor symptoms in cervical dystonia. Toxins, 13.","DOI":"10.3390\/toxins13090647"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00415-020-10217-7","article-title":"Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia","volume":"268","author":"Comella","year":"2021","journal-title":"J. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/17460441.2019.1623785","article-title":"New approaches to discovering drugs that treat dystonia","volume":"14","author":"Jinnah","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.toxicon.2017.09.004","article-title":"Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?","volume":"147","author":"Jinnah","year":"2018","journal-title":"Toxicon"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/jnnp.2003.013441","article-title":"Craniocervical dystonia questionnaire (CDQ-24): Development and validation of a disease-specific quality of life instrument","volume":"75","author":"Wissel","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e001853","DOI":"10.1136\/bmjopen-2012-001853","article-title":"An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport)","volume":"3","author":"Hefter","year":"2013","journal-title":"BMJ Open"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00702-020-02274-z","article-title":"Emotional well-being and pain could be a greater determinant of quality of life compared to motor severity in cervical dystonia","volume":"128","author":"Klingelhoefer","year":"2021","journal-title":"J. Neural. Transm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1539449217697043","article-title":"Measuring disability in patients with cervical dystonia according to the International Classification of Functioning, Disability and Health","volume":"37","author":"Cox","year":"2017","journal-title":"OTJR Occup. Particip. Health"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/01616412.2020.1796430","article-title":"Cervical dystonia: Factors deteriorating patient satisfaction of long-term treatment with botulinum toxin","volume":"42","author":"Marciniec","year":"2020","journal-title":"Neurol. Res."},{"key":"ref_46","first-page":"473","article-title":"Spasmodic torticollis: Clinical and biologic features and their implications for focal dystonia","volume":"50","author":"Duane","year":"1988","journal-title":"Adv. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0304-3959(96)03296-4","article-title":"Pain in spasmodic torticollis","volume":"69","author":"Kutvonen","year":"1997","journal-title":"Pain"},{"key":"ref_48","first-page":"445","article-title":"The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): Assessment of validity and inter-rater reliability","volume":"40","author":"Consky","year":"1990","journal-title":"Neurology"},{"key":"ref_49","unstructured":"Jankovic, J., and Hallet, M. (1994). Therapy with Botulinum Toxin, Marcel Dekker."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/5\/333\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:33:49Z","timestamp":1760124829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/5\/333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["toxins15050333"],"URL":"https:\/\/doi.org\/10.3390\/toxins15050333","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}